Loading...

Karo Pharma

DB:KA6N
Snowflake Description

Undervalued with proven track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
KA6N
DB
SEK6B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Karo Pharma AB (publ), a healthcare company, develops and markets products for pharmacies and the health care sectors in Sweden, Norway, Denmark, and Finland. The last earnings update was 12 days ago. More info.


Add to Portfolio Compare Print
KA6N Share Price and Events
7 Day Returns
-1.2%
DB:KA6N
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
15.8%
DB:KA6N
-10.2%
DE Biotechs
-6%
DE Market
KA6N Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Karo Pharma (KA6N) -1.2% 1.1% 0.1% 15.8% 15.2% -
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • KA6N outperformed the Biotechs industry which returned -10.2% over the past year.
  • KA6N outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
KA6N
Industry
5yr Volatility vs Market

Value

 Is Karo Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Karo Pharma to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Karo Pharma.

DB:KA6N Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 10.1%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:KA6N
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 22%) (46.16%))
1.649
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.65
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.649 * 5.96%)
10.06%

Discounted Cash Flow Calculation for DB:KA6N using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Karo Pharma is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:KA6N DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (SEK, Millions) Source Present Value
Discounted (@ 10.06%)
2019 522.32 Est @ 102.06% 474.59
2020 895.83 Est @ 71.51% 739.59
2021 1,344.87 Est @ 50.13% 1,008.85
2022 1,817.67 Est @ 35.16% 1,238.92
2023 2,266.23 Est @ 24.68% 1,403.51
2024 2,659.26 Est @ 17.34% 1,496.42
2025 2,983.91 Est @ 12.21% 1,525.68
2026 3,240.96 Est @ 8.61% 1,505.68
2027 3,438.60 Est @ 6.1% 1,451.52
2028 3,587.74 Est @ 4.34% 1,376.08
Present value of next 10 years cash flows SEK12,220.85
DB:KA6N DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= SEK3,587.74 × (1 + 0.23%) ÷ (10.06% – 0.23%)
SEK36,584.82
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= SEK36,584.82 ÷ (1 + 10.06%)10
SEK14,032.15
DB:KA6N Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= SEK12,220.85 + SEK14,032.15
SEK26,252.99
Equity Value per Share
(SEK)
= Total value / Shares Outstanding
= SEK26,252.99 / 161.87
SEK162.19
DB:KA6N Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:KA6N represents 0.09413x of OM:KARO
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.09413x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (SEK) x Listing Adjustment Factor
= SEK 162.19 x 0.09413
€15.27
Value per share (EUR) From above. €15.27
Current discount Discount to share price of €3.66
= -1 x (€3.66 - €15.27) / €15.27
76%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Karo Pharma is available for.
Intrinsic value
>50%
Share price is €3.66 vs Future cash flow value of €15.27
Current Discount Checks
For Karo Pharma to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Karo Pharma's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Karo Pharma's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Karo Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Karo Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:KA6N PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in SEK SEK4.63
OM:KARO Share Price ** OM (2019-04-18) in SEK SEK38.86
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Karo Pharma.

DB:KA6N PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:KARO Share Price ÷ EPS (both in SEK)

= 38.86 ÷ 4.63

8.39x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Karo Pharma is good value based on earnings compared to the Europe Biotechs industry average.
  • Karo Pharma is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does Karo Pharma's expected growth come at a high price?
Raw Data
DB:KA6N PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 8.39x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Karo Pharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Karo Pharma's assets?
Raw Data
DB:KA6N PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in SEK SEK21.97
OM:KARO Share Price * OM (2019-04-18) in SEK SEK38.86
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:KA6N PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:KARO Share Price ÷ Book Value per Share (both in SEK)

= 38.86 ÷ 21.97

1.77x

* Primary Listing of Karo Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Karo Pharma is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Karo Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Karo Pharma has a total score of 5/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Karo Pharma expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Karo Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.5%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Karo Pharma expected to grow at an attractive rate?
  • Unable to compare Karo Pharma's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Karo Pharma's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Karo Pharma's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:KA6N Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:KA6N Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:KA6N Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
DB:KA6N Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2018-12-31 1,615 318 657
2018-09-30 1,391 261 595
2018-06-30 1,132 92 551
2018-03-31 785 40 40
2017-12-31 658 34 15
2017-09-30 515 72 141
2017-06-30 463 84 133
2017-03-31 404 60 114
2016-12-31 347 -36 96
2016-09-30 308 -51 -20
2016-06-30 232 -62 -41
2016-03-31 151 -94 -60

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Karo Pharma is high growth as no earnings estimate data is available.
  • Unable to determine if Karo Pharma is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:KA6N Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Karo Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:KA6N Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
DB:KA6N Past Financials Data
Date (Data in SEK Millions) EPS *
2018-12-31 4.63
2018-09-30 4.77
2018-06-30 5.52
2018-03-31 0.44
2017-12-31 0.17
2017-09-30 1.77
2017-06-30 1.74
2017-03-31 1.56
2016-12-31 1.42
2016-09-30 -0.38
2016-06-30 -0.72
2016-03-31 -1.20

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Karo Pharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine whether Karo Pharma is trading at Karo Pharma'san attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  2. Karo Pharma's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Karo Pharma's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Karo Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Karo Pharma has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Karo Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Karo Pharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Karo Pharma has delivered over 20% year on year earnings growth in the past 5 years.
  • Karo Pharma's 1-year earnings growth exceeds its 5-year average (4428.6% vs 77.6%)
  • Karo Pharma's earnings growth has exceeded the Europe Biotechs industry average in the past year (4428.6% vs 18.2%).
Earnings and Revenue History
Karo Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Karo Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:KA6N Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1,615.11 657.38 521.48 0.62
2018-09-30 1,390.55 594.68 445.32 2.12
2018-06-30 1,132.32 551.13 369.17 2.33
2018-03-31 785.34 40.33 288.43 3.39
2017-12-31 657.61 14.52 242.26 4.36
2017-09-30 515.34 141.13 177.54 3.44
2017-06-30 463.41 133.19 157.90 5.09
2017-03-31 404.29 114.14 152.64 4.91
2016-12-31 347.26 95.56 141.48 5.26
2016-09-30 308.24 -19.97 129.64 10.04
2016-06-30 232.48 -40.82 109.73 13.12
2016-03-31 150.97 -59.52 77.41 28.91
2015-12-31 69.10 -77.63 53.87 34.96
2015-09-30 19.73 -75.25 25.89 53.77
2015-06-30 19.13 -68.58 23.58 63.21
2015-03-31 24.13 -61.25 22.94 62.22
2014-12-31 30.06 -59.28 21.01 68.59
2014-09-30 31.65 -40.85 20.43 56.24
2014-06-30 44.01 -24.42 20.46 51.66
2014-03-31 45.29 -24.79 20.78 53.03
2013-12-31 47.03 -22.08 20.43 52.53
2013-09-30 45.93 -27.69 20.04 53.55
2013-06-30 32.91 -46.85 20.20 60.16
2013-03-31 32.96 -54.88 21.88 66.84
2012-12-31 33.17 -98.25 25.12 107.86
2012-09-30 24.62 -139.94 22.89 137.28
2012-06-30 16.48 -178.37 29.01 162.88

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Karo Pharma has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Karo Pharma used its assets less efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Karo Pharma has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Karo Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Karo Pharma has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Karo Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Karo Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Karo Pharma's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Karo Pharma's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Karo Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Karo Pharma Company Filings, last reported 3 months ago.

DB:KA6N Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 3,611.00 2,903.25 398.58
2018-09-30 3,650.98 3,222.83 443.11
2018-06-30 3,657.57 3,154.84 333.30
2018-03-31 1,876.74 1,714.70 295.19
2017-12-31 1,586.52 2,264.42 838.59
2017-09-30 1,074.10 632.32 130.39
2017-06-30 1,061.86 631.87 150.19
2017-03-31 1,104.37 626.12 166.11
2016-12-31 717.01 915.50 121.35
2016-09-30 627.13 0.00 147.83
2016-06-30 621.64 0.00 157.64
2016-03-31 367.56 0.00 11.22
2015-12-31 364.58 119.29 76.49
2015-09-30 239.55 0.00 132.06
2015-06-30 24.02 0.00 19.09
2015-03-31 25.56 0.00 32.20
2014-12-31 40.91 0.00 51.61
2014-09-30 62.69 0.00 62.30
2014-06-30 72.60 0.00 71.93
2014-03-31 10.46 0.00 8.60
2013-12-31 23.84 0.00 22.80
2013-09-30 27.19 0.00 32.12
2013-06-30 20.67 0.00 33.79
2013-03-31 35.25 0.00 48.02
2012-12-31 45.92 0.28 54.07
2012-09-30 26.62 0.00 50.00
2012-06-30 39.26 0.00 75.41
  • Karo Pharma's level of debt (80.4%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 80.4% today).
  • Debt is not well covered by operating cash flow (11%, less than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 5x coverage).
X
Financial health checks
We assess Karo Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Karo Pharma has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Karo Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Karo Pharma dividends.
If you bought €2,000 of Karo Pharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Karo Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Karo Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:KA6N Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:KA6N Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
DB:KA6N Past Annualized Dividends Data
Date (Data in SEK) Dividend per share (annual) Avg. Yield (%)
2019-04-09 0.000 0.000
2019-02-14 0.000 0.000
2018-04-26 0.300 0.896
2018-04-12 0.300 0.904
2017-04-10 0.280 0.751

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Karo Pharma has not reported any payouts.
  • Unable to verify if Karo Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Karo Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Karo Pharma has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Karo Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Karo Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Karo Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Karo Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ulf Mattsson
AGE 54
TENURE AS CEO 0 years
CEO Bio

Mr. Ulf Mattsson, M.Sc. Econ., has been Interim Chief Executive Officer at Karo Pharma AB (publ) since April 03, 2019. He has been an Industrial Advisor at EQT Partners AB since 2008. Mr. Mattsson served as an Interim President and Interim Chief Executive Officer of Gambro AB since January 18, 2011 and served as its Chief Executive Officer. He was also employed at Securitas Direct and has been its Chairman of the Board since June 2007. He served as the President and Chief Executive Officer at Capio AB (publ) from January 1, 2006 to November 2006. He served as the President and Chief Executive Officer at Tarkett Inc. from 2000 to 2004. He served as Chief Executive Officer and Executive Vice President at Mölnlycke Health Care AB. He served as Head of North America and Member of the Executive Management Board at Tarkett Holding GmbH. He has been the Chairman and Director of Eltel AB (publ) since June 1, 2017. He serves as Chairman of the Board at Crem International Holding AB. He has been the Chairman at Evidensia Djursjukvård AB since 2014, Itslearning AS since 2013, Crem International AB since 2012, Granngården AB since 2014 and Musti ja Mirri OY since 2015. He served as the Chairman of Mackmyra Svensk Whisky AB. He served as the Chairman at AcadeMedia AB from 2010 to November 24, 2017. He has been a Director of Addtech AB (publ) since August 29, 2012. He has been a Director of Q-Med AB since February 2009. He serves as a Director of iFLOOR.com, Gambro AB and Granngården AB. He has been a Director of ORAS Invest OY (Oras Invest Ltd) since 2014. He has been a Director of Sanitek Europe Oway since 2009. He served as a Director of Mackmyra Svensk Whisky AB since 2011 and Bactiguard Holding AB (publ) since 2012. He served as a Director of StormGeo AS (now Stormgeo Holding AS) since April 2016. He served as a Director of Bactiguard AB. Mr. Mattsson served as a Director of Tarkett Inc. He served as an Independent Director of Sanitec Corporation (Sanitec Oyj) since 2009. He served as an Independent Non-executive Director of Verisure Holdings AB since 2006. He received a M.Sc. in Business Administration and Economics and Program for Management Development (PMD) from Harvard Business School. Mr. Mattsson holds BSc in Business and Economics from Stockholm University. He has BBA from Handelshögskolan i Stockholm.

CEO Compensation
  • Insufficient data for Ulf to compare compensation growth.
  • Insufficient data for Ulf to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team

Ulf Mattsson

TITLE
Interim Chief Executive Officer
AGE
54

Mats-Olof Wallin

TITLE
Chief Financial Officer
AGE
67
TENURE
1.3 yrs

Cecilia Thurell

TITLE
Operations Director
AGE
44

Mattias Nordström

TITLE
Sales Director
AGE
38

Lisa Westerdahl

TITLE
Marketing Director
AGE
44

SIMON Nyberg-Hansen

TITLE
Managing Director of Norway
AGE
52

Anette Abrahamsson

TITLE
Chief Medical & Regulatory Officer
AGE
49
Board of Directors Tenure

Average tenure and age of the Karo Pharma board of directors in years:

0.2
Average Tenure
60
Average Age
  • The average tenure for the Karo Pharma board of directors is less than 3 years, this suggests a new board.
Board of Directors

Bo Hansen

TITLE
Interim Chairman
AGE
60
TENURE
0.2 yrs

Per-Anders Johansson

TITLE
Director
COMPENSATION
SEK548K
AGE
64
TENURE
6.8 yrs

Thomas Hedner

TITLE
Director
COMPENSATION
SEK219K
AGE
69
TENURE
5.3 yrs

Marianne Hamilton

TITLE
Director
COMPENSATION
SEK136K
AGE
71
TENURE
2.3 yrs

Håkan Åström

TITLE
Director
COMPENSATION
SEK136K
AGE
71
TENURE
2.3 yrs

Erika Henriksson

TITLE
Director
AGE
37
TENURE
0.2 yrs

Vesa Koskinen

TITLE
Director
AGE
39
TENURE
0.2 yrs

Christoffer Lorenzen

TITLE
Director
AGE
43
TENURE
0.2 yrs

Åsa Riisberg

TITLE
Director
AGE
44
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • Karo Pharma insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
24. Jan 19 Sell Peter Blom Individual 22. Jan 19 22. Jan 19 -33,015 €3.71 €-122,417
07. Sep 18 Sell Nomic AB Company 05. Sep 18 05. Sep 18 -983,329 €3.13 €-3,078,091
04. Jun 18 Buy Carl Lindgren Individual 01. Jun 18 01. Jun 18 2,509 €2.33 €5,846
X
Management checks
We assess Karo Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Karo Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Karo Pharma AB (publ), a healthcare company, develops and markets products for pharmacies and the health care sectors in Sweden, Norway, Denmark, and Finland. The company’s development projects are focused on nuclear receptors as target proteins for the development of pharmaceuticals. Its products include Mabs medical compression socks to enhance blood circulation in the legs; Allévo nutritional products; Swereco ergonomic products for people with disabilities; and Dosett medicine storage products. The company also offers Triolif, an over-the-counter medicine for the treatment of sore throats; Vagisan, an over-the-counter product for the treatment of vaginal dryness for women; Plantur 39 for the treatment of hair; Slicks stockings and tights for legs; and BabySlide, a product to reduce lacerations during childbirth, as well as medicines for the treatment of pains, such as headache, toothache, menstrual pain, muscle pain, and joint pain. Its products under development include nuclear receptor RORgamma based products for the treatment of autoimmune diseases; compounds to treat multiple sclerosis and cancer; and T268A, a common cold spray. Karo Pharma AB (publ) markets and distributes its products through the retail market, health specialist stores, and convenience stores. The company was formerly known as Karo Bio AB (publ) and changed its name to Karo Pharma AB (publ) in March 2016. Karo Pharma AB (publ) was founded in 1987 and is headquartered in Stockholm, Sweden.

Details
Name: Karo Pharma AB (publ)
KA6N
Exchange: DB
Founded: 1987
SEK601,661,324
161,867,792
Website: http://www.karopharma.se
Address: Karo Pharma AB (publ)
Nybrokajen 7,
Stockholm,
Stockholm County, 111 48,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM KARO Common Shares OMX Nordic Exchange Stockholm SE SEK 06. Apr 1998
OTCPK KARB.F Common Shares Pink Sheets LLC US USD 06. Apr 1998
DB KA6N Common Shares Deutsche Boerse AG DE EUR 06. Apr 1998
LSE 0RAQ Common Shares London Stock Exchange GB SEK 06. Apr 1998
BATS-CHIXE KAROS Common Shares BATS 'Chi-X Europe' GB SEK 06. Apr 1998
Number of employees
Current staff
Staff numbers
80
Karo Pharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 20:38
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/02/14
Last earnings filing: 2019/04/09
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.